This article is more than 5 years old. Information may no longer be current.

Intracameral antibiotics show comparable safety

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BEIJING — Early study results show intracameral moxifloxacin is comparable in both endothelial cell loss and central corneal thickness with intracameral cefuroxime, according to a speaker here.

At the 25th APAO Congress, Kung Yong Then, MD, presented results of a clinical trial of 84 eyes of 77 patients who were randomized to receive either intracameral cefuroxime or intracameral moxifloxacin following cataract extraction and IOL implantation. A single surgeon performed all procedures and the same surgical technique and IOL was used in all cases.

At 1 week, 1 month and 3 months there was no statistically significant difference in endothelial cell count density or central corneal thickness changes, Dr. Then said.

Dr. Then also noted there were no statistically significant differences in postoperative visual acuity, anterior chamber cells or flare.